Literature DB >> 19742142

Maintenance Capecitabine for High-Risk Gastrointestinal Tumors: Everything That's Old Is New Again.

Laura Raftery1, Bert H O'Neil.   

Abstract

Entities:  

Year:  2009        PMID： 19742142      PMCID： PMC2739641     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  13 in total

1.  Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

Authors:  Guido Bocci; K C Nicolaou; Robert S Kerbel
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  Docetaxel (Taxotere) administered in weekly schedules.

Authors:  F A Greco
Journal:  Semin Oncol       Date:  1999-06       Impact factor: 4.929

3.  Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.

Authors:  S Regazzoni; G Pesce; G Marini; F Cavalli; A Goldhirsch
Journal:  Ann Oncol       Date:  1996-10       Impact factor: 32.976

4.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

5.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Authors:  Christophe Tournigand; Andres Cervantes; Arie Figer; Gérard Lledo; Michel Flesch; Marc Buyse; Laurent Mineur; Elisabeth Carola; Pierre-Luc Etienne; Fernando Rivera; Isabel Chirivella; Nathalie Perez-Staub; Christophe Louvet; Thierry André; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

6.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

Authors:  Silvia Dellapasqua; Francesco Bertolini; Vincenzo Bagnardi; Elisabetta Campagnoli; Eloise Scarano; Rosalba Torrisi; Yuval Shaked; Patrizia Mancuso; Aron Goldhirsch; Andrea Rocca; Elisabetta Pietri; Marco Colleoni
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

7.  Treatment of non-small-cell lung cancer with prolonged oral etoposide.

Authors:  S Kakolyris; G Samonis; M Koukourakis; I Vlachonicolis; G Chalkiadakis; K Kalbakis; I Souglakos; S Agelaki; P Toloudis; V Georgoulias
Journal:  Am J Clin Oncol       Date:  1998-10       Impact factor: 2.339

8.  Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies.

Authors:  Catharina Wenzel; Robert M Mader; Guenther G Steger; Ursula Pluschnig; Gabriela V Kornek; Werner Scheithauer; Gottfried J Locker
Journal:  Anticancer Drugs       Date:  2003-02       Impact factor: 2.248

Review 9.  Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data.

Authors:  William B Ershler
Journal:  Crit Rev Oncol Hematol       Date:  2006-02-13       Impact factor: 6.312

10.  Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.

Authors:  Roberto Petrioli; Alessandra Pascucci; Edoardo Francini; Stefania Marsili; Anna Ida Fiaschi; Serenella Civitelli; Gabriello Tanzini; Sandra Battistelli; Marco Lorenzi; Franco Roviello; Guido Francini
Journal:  Anticancer Drugs       Date:  2008-01       Impact factor: 2.248
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.